



## ***BioAlliance Pharma receives a guarantee from Coface to finance its export activities***

**Paris, January 3, 2013** - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the signature of an assurance prospection agreement with Coface granting a guarantee to finance its export activities.

Under this agreement, Coface will cover the expenses incurred by BioAlliance Pharma in the prospect of export markets for an overall amount of €1.3 million. This financing aims at expanding throughout the world, and particularly in emerging countries, the commercialization of Loramyc<sup>®</sup>, a miconazole Lauriad<sup>™</sup> mucoadhesive buccal tablet, indicated for the treatment of oropharyngeal candidiasis in immunocompromised patients.

*"We are very pleased to have obtained from Coface this guarantee of a significant amount. It will enable us to reinforce and to accelerate our strategy to expand the commercialization of Loramyc<sup>®</sup> towards markets with strong economic growth",* declares Judith Greciet, CEO of BioAlliance Pharma.

### **About Coface**

Coface manages on behalf of and with the guarantee of the French State, a wide range of products aiming at facilitating French exportations, by supporting companies throughout their export process. This offer includes five guarantees: assurance prospection, exporter risk insurance, export credit insurance, exchange risk insurance and investment insurance. All public guarantees included, Coface provides today insurance to more than 8,000 companies.

## **About BioAlliance Pharma**

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

### **Specialty products**

Loramyc<sup>®</sup>/Oravig<sup>®</sup> (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir<sup>®</sup>/Sitavig<sup>®</sup> (Acyclovir Lauriad<sup>™</sup>) (labialis herpes): Registered in 8 European countries, registration status in the US

Fentanyl Lauriad<sup>™</sup> (chronic cancer pain): Positive preliminary Phase I results

### **Orphan Oncology products**

Livatag<sup>®</sup> (Doxorubicin Transdrug<sup>™</sup>) (primary liver cancer): Phase III on going

Validive<sup>®</sup> (Clonidine Lauriad<sup>™</sup>) (mucositis): Phase II on going

AMEP<sup>®</sup> (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2011 Reference Document filed with the AMF on April 24, 2012, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).*

#### **BioAlliance Pharma SA**

Judith Greciet, CEO

Tel +33 1 45 58 76 00

[judith.greciet@bioalliancepharma.com](mailto:judith.greciet@bioalliancepharma.com)

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71

[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

#### **ALIZE RP**

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

[caroline@alizerp.com](mailto:caroline@alizerp.com)

Emilie Dèbes

Tel.: +33 1 42 68 86 40

[emilie@alizerp.com](mailto:emilie@alizerp.com)